Literature DB >> 11530353

New World monkey efficacy trials for malaria vaccine development: critical path or detour?

D G Heppner1, J F Cummings, C Ockenhouse, K E Kester, J A Lyon, D M Gordon.   

Abstract

Neither GMP malaria antigens nor GMP vaccines have been compared for efficacy in monkeys and humans. It is too risky to base categorical (go/no go) development decisions on results obtained using partially characterized (non-GMP) antigens, adjuvants that are too toxic for human use or unvalidated primate models. Such practices will lead to serious errors (e.g. failure to identify and stop flawed efforts, rejection of effective vaccine strategies) and unjustifiable delays. Successful malaria vaccine development will emphasize definitive field trials in populations at risk of malaria to define and improve vaccine efficacy.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11530353     DOI： 10.1016/s1471-4922(01)02012-8

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN： 1471-4922


  5 in total

1.  Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion.

Authors:  Karen Hayton; Deepak Gaur; Anna Liu; Jonathan Takahashi; Bruce Henschen; Subhash Singh; Lynn Lambert; Tetsuya Furuya; Rachel Bouttenot; Michelle Doll; Fatima Nawaz; Jianbing Mu; Lubin Jiang; Louis H Miller; Thomas E Wellems
Journal:  Cell Host Microbe       Date:  2008-07-17       Impact factor: 21.023

2.  Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.

Authors:  Ivette Caro-Aguilar; Alexandra Rodríguez; J Mauricio Calvo-Calle; Fanny Guzmán; Patricia De la Vega; Manuel Elkin Patarroyo; Mary R Galinski; Alberto Moreno
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

3.  The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.

Authors:  Christian A Darko; Evelina Angov; William E Collins; Elke S Bergmann-Leitner; Autumn S Girouard; Stacy L Hitt; Jana S McBride; Carter L Diggs; Anthony A Holder; Carole A Long; John W Barnwell; Jeffrey A Lyon
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.

Authors:  George Jiang; Yupin Charoenvit; Alberto Moreno; Maria F Baraceros; Glenna Banania; Nancy Richie; Steve Abot; Harini Ganeshan; Victoria Fallarme; Noelle B Patterson; Andrew Geall; Walter R Weiss; Elizabeth Strobert; Ivette Caro-Aquilar; David E Lanar; Allan Saul; Laura B Martin; Kalpana Gowda; Craig R Morrissette; David C Kaslow; Daniel J Carucci; Mary R Galinski; Denise L Doolan
Journal:  Malar J       Date:  2007-10-09       Impact factor: 2.979

5.  Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.

Authors:  David R Cavanagh; Clemens H M Kocken; John H White; Graeme J M Cowan; Kay Samuel; Martin A Dubbeld; Annemarie Voorberg-van der Wel; Alan W Thomas; Jana S McBride; David E Arnot
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.